News about "Shilpa Medicare"

Koanna International and PPI to Form JV to Build New Pharma Manufacturing Facility in Saudi Arabia

Koanna International and PPI to Form JV to Build New Pharma Manufacturing Facility in Saudi Arabia

Pharma Pharmaceutical Industries & Biological Products (PPI) of Saudi Arabia and Koanna International FZ LLC, a wholly-owned subsidiary of Shilpa Medicare, have signed a definitive agreement to establish a joint venture to set up a pharma manufacturing facility in Saudi Arabia.

Shilpa Medicare | 28/08/2025 | By Mrinmoy Dey

Shilpa Medicare Secures CDSCO Approval for NorUDCA Tablets in NAFLD Treatment

Shilpa Medicare Secures CDSCO Approval for NorUDCA Tablets in NAFLD Treatment

Shilpa Medicare Ltd has received approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).

Shilpa Medicare | 16/08/2025 | By Dineshwori 121

Alveolus Bio Secures Strategic Investment from Shilpa Medicare

Alveolus Bio Secures Strategic Investment from Shilpa Medicare

Alveolus Bio has announced a strategic financing round led by Shilpa Medicare, which will also serve as its exclusive global development and manufacturing partner to accelerate clinical advancement of its inhaled biotherapeutics for respiratory diseases.

Shilpa Medicare | 04/08/2025 | By Mrinmoy Dey

Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma

BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.

Shilpa Medicare | 07/04/2025 | By Aishwarya 122

Shilpa Medicare Gets SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets

Shilpa Medicare Gets SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets

Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets.

Shilpa Medicare | 12/03/2025 | By Aishwarya 403

Shilpa Medicare Launches ORAAL for the Treatment of Oral Mucositis

Shilpa Medicare Launches ORAAL for the Treatment of Oral Mucositis

ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association.

Shilpa Medicare | 16/10/2023 | By Manvi 746

Shilpa Medicare gets two minor observations from US FDA at Hyderabad facility

Shilpa Medicare gets two minor observations from US FDA at Hyderabad facility

The observations were noticed at Unit VII, Analytical Services Division

Shilpa Medicare | 13/03/2023 | By Sudeep Soparkar 1084

Shilpa Medicare registers Bengaluru facility with Ministry of Health, UAE

Shilpa Medicare registers Bengaluru facility with Ministry of Health, UAE

The facility is involved in the manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems

Shilpa Medicare | 20/02/2023 | By Sudeep Soparkar 887

Shilpa Medicare's Telangana facility bags Health Canada GMP approval

Shilpa Medicare's Telangana facility bags Health Canada GMP approval

The facility is involved in the manufacturing, packaging, labelling and testing of finished dosage forms

Shilpa Medicare | 01/12/2022 | By Sudeep Soparkar 503

Shilpa Medicare's plant in Telangana bags US FDA clearance

Shilpa Medicare's plant in Telangana bags US FDA clearance

The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited (Parent Organization) and its agreed parties

Shilpa Medicare | 23/09/2022 | By Sudeep Soparkar 846


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members